Chris Andrews (singer) then a string of hits for Sandie Shaw. They included "Girl Don't Come" (No. 3, 1964/65), "I'll Stop at Nothing" (No. 4, 1965), "Message Understood" (No. 6, 1965) and "Long Live Love" (No. 1, 1965). The latter remained a chart topper in the UK Singles Chart for three weeks. "Girl Don't Come" was covered by Cher on her debut album, "All I Really Want to Do". Also in 1965, Andrews as a solo artist, got to No. 3 in the same listings with "Yesterday Man", which peaked in Germany at No. 1 for four weeks; followed up with a No.
YM Biosciences the Toronto Stock Exchange and the New York Stock Exchange. YM BioSciences was the first company from any major-market country to enter into a relationship with the Cuban Government for the development of a number of that country's biopharmaceuticals, with first licenses concluding in 1995. In 1994, the company created a joint venture with Centro de Inmunología Molecular (CCIMAB) in Cuba called CIMYM BioSciences. The joint venture developed the Nimotuzumab drug. In February 2013, Gilead Sciences completed the acquisition of YM Biosciences for US $510 million. YM BioSciences' principal medicine of interest was a monoclonal antibody – Nimotuzumab – targeting